OVERVIEW

Nursing Voices From the Frontline: Adjuvant CDK4/6 Therapy in HR+ HER2- Breast Cancer is organized by Medical Learning Institute Inc (MLI).

Release Date: May 20, 2026
Expiration Date: May 19, 2027

Description:
Nursing Voices From the Frontline: Adjuvant CDK4/6 Therapy in HR+ HER2- Breast Cancer

Adjuvant CDK4/6 inhibitors reduce recurrence risk in high-risk HR+, HER2- early breast cancer—yet adherence and toxicity management remain critical challenges. This on-demand program empowers oncology nurses and NPs with practical strategies to translate evidence into patient-centered care. 

Through case-based learning and expert insights, participants will strengthen skills in recurrence risk assessment, proactive monitoring and management of adverse events (including neutropenia, GI toxicities, and ILD/pneumonitis), dose adjustment principles, and nursing-led interventions that promote long-term adherence and persistence. Downloadable quick-reference tools reinforce real-world application. 

Learning Objectives:
After completing this activity, the participant should be better able to: 

  • Incorporate clinical evidence on CDK4/6 inhibitor-containing adjuvant therapy into treatment plans for patients with high-risk hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) early breast cancer (EBC) 
  • Develop supportive approaches to proactively monitor and mitigate adverse events (AEs) associated with CDK4/6 inhibitor-containing regimens in patients with HR+, HER2- EBC? 
  • Implement multidisciplinary strategies to improve patient adherence and persistence to adjuvant CDK4/6 inhibitor therapies, including patient-centered nursing approaches 
Credits

Credits:
In support of improving patient care, Medical Learning Institute Inc is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

PA:
Medical Learning Institute Inc has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until May 19, 2027. PAs should only claim credit commensurate with the extent of their participation.

Nursing Continuing Professional Development:
Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour and 1.0 contact hour(s) in the area of pharmacology. 

Interprofessional Continuing Education (IPCE) Statement:
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. 

  • 1 AAPA
  • 1 Contact Hours
  • 1 IPCE
  • TARGET AUDIENCE

    NursingPhysician AssistantOncologistsNurse Practitioners

    SPECIALITIES

    OncologyNursing

    RELATED ONLINE COURSES